Tissue | 3 h* | 6 h* | 24 h* | |||
---|---|---|---|---|---|---|
131I-c-MOv18 | 125I-c-MOv18 | 131I-c-MOv18 | 125I-c-MOv18 | 131I-c-MOv18 | 125I-c-MOv18 | |
Blood | 23.1 ± 1.4 | 23.2 ± 1.4 | 17.3 ± 0.4 | 17.8 ± 0.4 | 12.3 ± 0.8 | 13.4 ± 0.6 |
Tumor† | 7.6 ± 0.7 | 7.0 ± 0.6 | 8.8 ± 1.3 | 8.2 ± 1.2 | 12.7 ± 0.6 | 10.9 ± 0.5 |
Liver† | 4.3 ± 0.3 | 3.8 ± 0.3 | 3.2 ± 0.4 | 2.9 ± 0.3 | 2.1 ± 0.3 | 2.0 ± 0.2 |
Spleen | 3.9 ± 0.4 | 3.8 ± 0.4 | 4.0 ± 1.1 | 3.8 ± 1.0 | 2.1 ± 0.3 | 2.2 ± 0.3 |
Lung | 5.6 ± 0.4 | 5.7 ± 0.4 | 4.6 ± 0.1 | 4.7 ± 0.2 | 3.7 ± 0.4 | 3.9 ± 0.3 |
Muscle | 0.6 ± 0.1 | 0.6 ± 0.1 | 0.5 ± 0.1 | 0.5 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 |
Kidney | 4.9 ± 0.6 | 4.8 ± 0.6 | 3.5 ± 0.2 | 3.5 ± 0.2 | 2.5 ± 0.4 | 2.6 ± 0.3 |
Heart | 3.7 ± 0.2 | 3.7 ± 0.2 | 3.1 ± 0.2 | 3.1 ± 0.1 | 2.2 ± 0.2 | 2.3 ± 0.2 |
Colon | 1.4 ± 0.2 | 1.4 ± 0.2 | 1.4 ± 0.2 | 1.4 ± 0.2 | 0.9 ± 0.1 | 0.9 ± 0.1 |
Ileum | 2.1 ± 0.1 | 2.1 ± 0.1 | 1.8 ± 0.2 | 1.8 ± 0.2 | 1.1 ± 0.1 | 1.2 ± 0.1 |
Stomach | 0.7 ± 0.2 | 0.7 ± 0.2 | 1.0 ± 0.1 | 0.9 ± 0.1 | 1.4 ± 0.2 | 1.4 ± 0.1 |
Bladder | 2.7 ± 0.1 | 2.6 ± 0.1 | 3.0 ± 0.1 | 3.1 ± 0.1 | 3.2 ± 0.2 | 3.4 ± 0.2 |
Sternum | 1.5 ± 0.2 | 1.5 ± 0.2 | 1.1 ± 0.1 | 1.1 ± 0.1 | 1.1 ± 0.1 | 1.1 ± 0.1 |
Fat | 0.5 ± 0.2 | 0.5 ± 0.2 | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.6 ± 0.1 | 0.6 ± 0.1 |
Skin | 2.9 ± 0.2 | 3.0 ± 0.2 | 3.3 ± 0.4 | 3.2 ± 0.4 | 3.6 ± 0.3 | 3.8 ± 0.2 |
↵* Time after injection. Results are expressed as percentage injected dose/g (mean ± SEM of four animals per obduction time).
↵† Significantly higher uptake of 131I-c-MOv18 in comparison with 125I-c-MOv18 was found in tumor at 3 h after injection (P = 0.031), at 6 h after injection (P = 0.007), and at 24 h after injection (P = 0.001) and in liver at 3 h after injection (P = 0.020); tumor size of 3-h group, 0.01–0.34 g; of 6-h group, 0.03–0.41 g; and of 24-h group, 0.18–0.59 g.